MetLife Investment Management’s Esperion Therapeutics ESPR Stock Holding History

MetLife Investment Management’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$469K	Buy	148,375 +51,723	+54%	+$145K	﹤0.01%	1942
2026 Q1	$265K	Sell	96,652 -33,083	-26%	-$105K	﹤0.01%	2080
2025 Q4	$480K	Buy	129,735 +23,259	+22%	+$75.2K	﹤0.01%	1807
2025 Q3	$282K	Sell	106,476 -16,027	-13%	-$31K	﹤0.01%	2120
2025 Q2	$121K	Buy	122,503 +47,717	+64%	+$47.8K	﹤0.01%	2450
2025 Q1	$108K	Sell	74,786 -42,946	-36%	-$79.1K	﹤0.01%	2491
2024 Q4	$259K	Buy	117,732 +46,682	+66%	+$109K	﹤0.01%	2164
2024 Q3	$117K	Buy	71,050 +22,734	+47%	+$45.9K	﹤0.01%	2565
2024 Q2	$107K	Buy	+48,316	New	+$114K	﹤0.01%	2571
2023 Q2	–	Sell	-13,642	Closed	-$21.7K	–	2954
2023 Q1	$21.7K	Sell	13,642 -21,044	-61%	-$109K	﹤0.01%	2771
2022 Q4	$216K	Hold	34,686	–	–	﹤0.01%	2202
2022 Q3	$232K	Buy	34,686 +4,925	+17%	+$33.8K	﹤0.01%	2197
2022 Q2	$189K	Sell	29,761 -5,349	-15%	-$30.3K	﹤0.01%	2362
2022 Q1	$163K	Buy	+35,110	New	+$151K	﹤0.01%	2474
2021 Q4	–	Sell	-5,894	Closed	-$71K	–	2519
2021 Q3	$71K	Sell	5,894 -6,792	-54%	-$98.9K	﹤0.01%	2512
2021 Q2	$268K	Hold	12,686	–	–	﹤0.01%	1965
2021 Q1	$356K	Hold	12,686	–	–	﹤0.01%	1716
2020 Q4	$330K	Hold	12,686	–	–	﹤0.01%	1707
2020 Q3	$472K	Hold	12,686	–	–	0.01%	1392
2020 Q2	$651K	Buy	12,686 +1,785	+16%	+$74.7K	0.01%	1239
2020 Q1	$344K	Hold	10,901	–	–	﹤0.01%	1418
2019 Q4	$650K	Hold	10,901	–	–	0.01%	1311
2019 Q3	$400K	Hold	10,901	–	–	﹤0.01%	1546
2019 Q2	$507K	Sell	10,901 -21,802	-67%	-$1.02M	0.01%	1472
2019 Q1	$1.31M	Buy	32,703 +21,802	+200%	+$978K	﹤0.01%	1504
2018 Q4	$501K	Hold	10,901	–	–	0.01%	1369
2018 Q3	$484K	Hold	10,901	–	–	0.01%	1571
2018 Q2	$427K	Buy	10,901 +3,363	+45%	+$170K	0.01%	1499
2018 Q1	$545K	Hold	7,538	–	–	0.01%	1323
2017 Q4	$496K	Buy	+7,538	New	+$406K	0.01%	1392

Other funds holding ESPR

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Trium Capital London, United Kingdom $79.4M AUM 36.67% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

MetLife Investment Management's ESPR Position: Q2 2026 in Review

MetLife Investment Management increased its Esperion Therapeutics (ESPR) stake by 54% in Q2 2026, buying an estimated $145K and bringing the position to 148,375 shares worth $469K. The position accounts for ﹤0.01% of the portfolio, ranked #1942.

MetLife Investment Management first reported a position in ESPR in Q4 2017 and has held it in 30 quarters since. The position peaked at $1.31M in Q1 2019. 192 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

MetLife Investment Management held 148,375 shares of Esperion Therapeutics worth $469K as of Q2 2026.
MetLife Investment Management bought 51,723 Esperion Therapeutics shares in Q2 2026, an estimated $145K.
Esperion Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #1942 holding.
MetLife Investment Management first reported a position in Esperion Therapeutics in Q4 2017 and has held it in 30 quarters since.
MetLife Investment Management's Esperion Therapeutics position peaked at $1.31M in Q1 2019.
192 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.